Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small ribosomal subunit protein mS39, mitochondrial (PTCD3) is a mitochondrial RNA-binding protein that is a component of the mitochondrial small ribosomal subunit, playing a crucial role in mitochondrial translation by binding rRNA and contributing to the assembly and function of the mitochondrial ribosome. Mutations in PTCD3 have been associated with combined oxidative phosphorylation deficiency 51, implicating its importance in mitochondrial respiratory chain function[1][2][7][8]. Notes: - PTCD3 is not a typical therapeutic target such as a receptor, enzyme, transporter, or transcription factor, but rather a structural/functional ribosomal protein essential for mitochondrial gene expression and respiratory function[1][7][8]. - There are no known drugs or small molecules directly targeting PTCD3; thus, no mechanisms of action, biomarkers, or safety concerns directly related to therapeutics are reported for this molecule. - Aliases provided here are based on common entries in gene/protein databases and literature[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small ribosomal subunit protein mS39, mitochondrial (PTCD3).